PROTEUS Trial at ASCO 2026: Perioperative Apalutamide Plus ADT in high-risk localized or locally advanced prostate cancer
oncodaily - PROTEUS trial, was presented during the ASCO 2026 Plenary Session by Mary-Ellen Taplin, MD, FASCO. The study evaluated one year of perioperative apalutamide plus androgen deprivation therapy in patients with […]
AI Summary: A perioperative strategy adding apalutamide to androgen‑deprivation therapy around radical prostatectomy shows improved outcomes for men with high‑risk or locally advanced prostate cancer, reducing metastasis and disease‑related death. Findings were highlighted and debated at ASCO sessions, prompting discussion about changing perioperative standards — and yes, surgeons are already updating their talking points.
- Industry, webinars and social media amplification of ASCO results (3)
- On-the-ground clinician reaction and emerging cN1 debate (3)
- PROTEUS trial: perioperative apalutamide reduces metastasis and death (3)
Industry, webinars and social media amplification of ASCO results
On-the-ground clinician reaction and emerging cN1 debate
PROTEUS trial: perioperative apalutamide reduces metastasis and death
Ascension must sell 7 ASCs to complete $3.9B AmSurg deal: FTC
Alan Condon / beckershospitalreview - St. Louis-based Ascension has received Federal Trade Commission approval to move forward with its planned acquisition of AmSurg — an ambulatory surgery center operator with more than 250 facilities across 34 states — but only after agreeing to divest seve…
AI Summary: The Federal Trade Commission approved Ascension’s $3.9 billion acquisition of AmSurg only after ordering divestitures of specific ambulatory surgery centers to preserve competition. Ascension must sell those ASCs before closing to prevent local market concentration and potential price hikes — because apparently somebody still has to protect patients from monopolies.
CMS releases Medicaid work requirements guidance for states
Rebecca Pifer Parduhn / healthcaredive - The highly anticipated interim final rule weighs in on key issues for states hustling to operationalize work requirements before the 2027 deadline. But there’s still some gray area — and lots of critics.
AI Summary: The Centers for Medicare & Medicaid Services released a national framework for implementing Medicaid work requirements, giving states guidance on eligibility, reporting and enforcement. The directive outlines guardrails and operational expectations while leaving significant discretion to states, prompting debate over access, administrative burden and potential gaps in coverage during rollout.
Massachusetts sues UnitedHealthcare over alleged $100M in fraudulent Medicaid payments
Elizabeth Casolo / beckershospitalreview - Massachusetts filed a lawsuit against UnitedHealthcare, accusing the insurer of retaining more than $100 million in fraudulent Medicaid payments. The May 29 complaint, filed in a state court, focuses on UnitedHealthcare’s role as a contractor for “Senior …
AI Summary: The Massachusetts attorney general filed a civil suit accusing UnitedHealthcare of submitting improper Medicaid payments, alleging roughly $100 million in fraudulent claims tied to managed‑care contracts. The action seeks recovery and oversight remedies as state regulators press insurers on billing practices, underscoring growing scrutiny of Medicaid managed‑care arrangements.
Florida hospitals lose $2B opioid lawsuit against pharmacies
Ella Jeffries / beckershospitalreview - A Florida judge has ruled in favor of CVS, Walgreens and Walmart in a lawsuit brought by 16 hospitals seeking $2 billion in damages related to the opioid epidemic. Broward County Chief Judge Carol-Lisa Phillips entered judgment for the defendants May 26, …
AI Summary: A Florida court ruling overturned a multibillion‑dollar claim by hospitals against major pharmacy chains, finding in favor of CVS, Walgreens and Walmart in litigation tied to the opioid epidemic. The decision removes a major anticipated payout and reshapes liability questions in the national effort to hold corporate actors accountable for addiction harms — legal teams are predictably thrilled.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC
oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]
AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.
OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s
discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.
UnitedHealthcare to nix nearly two thirds of pediatric prior auths
fiercehealthcare - UnitedHealthcare is set to eliminate close to two-thirds of pediatric prior authorization requirements by the end of the year.
AI Summary: UnitedHealthcare announced a major rollback of pediatric prior authorization requirements, eliminating roughly two‑thirds of those rules to reduce administrative burden and speed care for children. The move aims to ease clinician frustration and patient delays, while insurers and providers brace for workflow and cost‑management implications.
In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
Annie Sciacca / kffhealthnews - Conservative Shasta County stopped a measles outbreak from spreading, enlisting teachers, church leaders, and other trusted community members to get the public on board with health guidelines. Infectious disease specialists say the successful effort could…
AI Summary: Public health teams in a vaccine-hesitant California county deployed a targeted containment strategy—rapid case isolation, focused vaccination drives, community outreach and tailored messaging—to curb a measles flare-up. The approach balanced enforcement and engagement, showing that pragmatic, locally adapted tactics can control outbreaks even where vaccine acceptance is low.
Not just ovaries—new name for PCOS reflects the condition's multisystem nature
medicalxpress - An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In actuality, the condition is a broader metabolic and hormon…
AI Summary: Medical experts announced a name change for polycystic ovary syndrome to better reflect its multisystem effects rather than framing it solely as an ovarian disorder. The update aims to reduce stigma, encourage holistic management of metabolic and psychological comorbidities, and align terminology with current scientific understanding of the condition.
Care navigation startup Garner Health banks $100M series E at $2.74B valuation
fiercehealthcare - The startup plans to use the capital to expand its provider quality platform, scale AI-powered product innovation and expand access.
AI Summary: Care navigation platform Garner Health closed a $100 million financing round to scale patient navigation and referrals to high‑performing clinicians, drawing strategic participation including Kaiser. The funding fuels expansion of tech‑enabled matchmaking between patients and clinicians while investors chase better outcomes and lower downstream costs.
American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing
cancer - ACS researchers aim to reduce colorectal cancer deaths by offering options to improve screening participation
AI Summary: American Cancer Society revised colorectal screening guidelines, elevating at‑home stool testing and clarifying the role of blood‑based assays. Recommendations stress broader access to noninvasive stool tests while urging cautious, limited use of blood tests where appropriate, aiming to expand screening uptake without sacrificing diagnostic accuracy or overwhelming follow‑up resources.
- ACS guideline update: expanding stool tests, cautious blood-test role (7)
- Blood-based detection and ctDNA: trials shaping screening and treatment (4)
- All Other Stories
ACS guideline update: expanding stool tests, cautious blood-test role
Blood-based detection and ctDNA: trials shaping screening and treatment
All Other Stories
Walmart, Teladoc Team Up to Expand Access to Virtual Care
Marissa Plescia / medcitynews - Through a new partnership, Teladoc Health’s virtual services are now available on Walmart’s Better Care Services platform.The post Walmart, Teladoc Team Up to Expand Access to Virtual Care appeared first on MedCity News.
AI Summary: Walmart has integrated Teladoc’s virtual care services into its digital health platform, rolling out expanded telemedicine access through its channels. The partnership merges Teladoc’s clinical offerings with Walmart’s scale to lower barriers to care, steer routine visits online, and extend convenient virtual options to price‑sensitive consumers — because waiting rooms are so last century.
CMS Finalizes Rule to Simplify Payer-Provider Disputes Under No Surprises Act
Katie Adams / medcitynews - CMS finalized a new rule aimed at streamlining the No Surprises Act’s overwhelmed arbitration system. Provider groups largely welcomed the reforms — though some industry leaders said additional changes are still needed to address alleged misuse and improv…
AI Summary: The Centers for Medicare & Medicaid Services finalized a rule to simplify payer‑provider disputes under the No Surprises Act, updating the dispute resolution process and implementing a payer registry and portal changes. The aim is to reduce administrative friction, speed dispute handling, and make billing arbitration less of an endurance sport for providers and insurers.
- Final rule: new portal and payer registry details (3)
- Insurers push back; provider legal fights over payments (3)
- Patient fallout: medical debt and surprise billing stories (3)
Final rule: new portal and payer registry details
Insurers push back; provider legal fights over payments
Patient fallout: medical debt and surprise billing stories
Simple blood test could lead to personalized lung cancer treatment
medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…
AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.
- Blood tests for monitoring and personalizing lung cancer care (4)
- MCED trials and clinical benefit debate (4)
- Methylation liquid biopsy methods and applications (4)
- All Other Stories
Blood tests for monitoring and personalizing lung cancer care
MCED trials and clinical benefit debate
Methylation liquid biopsy methods and applications
All Other Stories
CVS sues to challenge new Tennessee PBM-pharmacy breakup law
Rebecca Pifer Parduhn / healthcaredive - The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in suit filed Friday.
AI Summary: CVS Health has filed suit challenging Tennessee's new law that bars pharmacy benefit managers from owning pharmacies, arguing the measure unlawfully disrupts established business models and harms patient access. The company seeks to block enforcement while the legal fight plays out, setting up a clash between state regulators and a major healthcare middleman.
Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.
AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.